Inhibikase Therapeutics Inc (IKT)

Apr 20, 2026

Inhibikase Therapeutics (IKT) asks shareholders to add 3M plan shares - Stock Titan

Apr 20, 2026

Apr 19, 2026

Inhibikase enrolls first patient in phase 3 PAH trial - MSN

Apr 19, 2026

Apr 18, 2026

Inhibikase Therapeutics (IKT) Stock Trading Today (+7.65%) 2026-04-18Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Apr 17, 2026

Inhibikase Therapeutics | SCHEDULE 13G/A: Others - Moomoo

Apr 17, 2026

Apr 16, 2026

Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat

Apr 16, 2026

Apr 14, 2026

Inhibikase Enrolls First Patient in Phase 3 PAH Trial - MyChesCo

Apr 14, 2026

Apr 13, 2026

Inhibikase grants stock options to five new employees - MSN

Apr 13, 2026

Apr 10, 2026

First patient enrolled in Phase 3 trial of PAH treatment IKT-001 - Pulmonary Hypertension News

Apr 10, 2026

Apr 10, 2026

MACD Signal: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill

Apr 10, 2026

Apr 08, 2026

Inhibikase Grants Stock Options to Five New Employees - MyChesCo

Apr 08, 2026

Apr 08, 2026

H.C. Wainwright reiterates Inhibikase stock rating on trial progress By Investing.com - Investing.com Canada

Apr 08, 2026

Apr 08, 2026

H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com

Apr 08, 2026

Apr 08, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Apr 08, 2026

Apr 08, 2026

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Sahm

Apr 08, 2026

Apr 07, 2026

Inhibikase Therapeutics Begins Enrollment for PAH Drug Trial - National Today

Apr 07, 2026

Apr 07, 2026

Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 IMPROVE-PAH Study for Pulmonary Arterial Hypertension Treatment 1 - Minichart

Apr 07, 2026

Apr 07, 2026

Inhibikase enrolls first patient in Phase 3 PAH drug trial By Investing.com - Investing.com South Africa

Apr 07, 2026

Apr 07, 2026

Inhibikase Therapeutics (IKT) Begins Key Phase 3 Trial Enrollmen - GuruFocus

Apr 07, 2026

Apr 07, 2026

Inhibikase Therapeutics Enrolls First Patient In Phase 3 Trial For Pulmonary Arterial Hypertension - marketscreener.com

Apr 07, 2026

Apr 07, 2026

Inhibikase Begins Pivotal Phase 3 Trial in PAH - TipRanks

Apr 07, 2026

Apr 07, 2026

Inhibikase enrolls first patient in Phase 3 PAH drug trial - Investing.com

Apr 07, 2026

Apr 07, 2026

Inhibikase Announces First Patient Enrolled in Global Phase 3 IMPROVE-PAH Trial of IKT-001 - TradingView

Apr 07, 2026

Apr 07, 2026

First patient dosed in Inhibikase (IKT) global Phase 3 IMPROVE-PAH trial of IKT-001 - Stock Titan

Apr 07, 2026

Apr 07, 2026

Springer Publishing Company & Cashmere Announce Partnership to Bring Trusted Healthcare Education Content to AI Systems - Weekly Voice

Apr 07, 2026

Apr 07, 2026

Inhibikase Therapeutics Announces Enrollment of First - GlobeNewswire

Apr 07, 2026

Apr 06, 2026

Inhibikase grants stock options to new employees under inducement plan - MSN

Apr 06, 2026

Apr 06, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Apr 06, 2026

Apr 05, 2026

Inhibikase Grants Stock Options to New Employees Under Inducement Plan - MyChesCo

Apr 05, 2026

Apr 04, 2026

IKT Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 04, 2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛

Apr 04, 2026

Apr 03, 2026

Inhibikase Therapeutics Announces Inducement Grants - National Today

Apr 03, 2026

Apr 03, 2026

Inhibikase Therapeutics Grants Inducement Shares to New Hires - National Today

Apr 03, 2026

Apr 03, 2026

IKT Stock Analysis: Inhibikase Therapeutics Inc 0.55% dip at $1.8, biotech performance review - Cổng thông tin điện tử Tỉnh Sơn La

Apr 03, 2026

Apr 02, 2026

HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings - Defense World

Apr 02, 2026

Apr 01, 2026

Nocion Therapeutics Appoints Mark Iwicki To Board - citybiz

Apr 01, 2026

Apr 01, 2026

HC Wainwright Issues Positive Estimate for IKT Earnings - MarketBeat

Apr 01, 2026

Mar 31, 2026

Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright - The Globe and Mail

Mar 31, 2026

Mar 30, 2026

H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Mar 30, 2026

Mar 28, 2026

Death Cross: What is the next catalyst for Inhibikase Therapeutics Inc2026 Update & Safe Capital Investment Plans - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

Inhibikase Therapeutics, Inc. 2025 Annual Report: Pipeline, Intellectual Property, and PAH Drug Development Overview - Minichart

Mar 27, 2026

Mar 26, 2026

Inhibikase Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2026

Mar 26, 2026

Inhibikase Therapeutics 10-K: Operating loss $51.97M, Net loss $48.26M, Interest income $3.72M - TradingView

Mar 26, 2026

Mar 26, 2026

Inhibikase (NASDAQ: IKT) pivots to PAH drug IKT-001 with Phase 3 trial and $115M raise - Stock Titan

Mar 26, 2026

Mar 26, 2026

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 26, 2026

Mar 26, 2026

Inhibikase (NASDAQ: IKT) boosts cash as 2025 loss grows and PAH Phase 3 advances - Stock Titan

Mar 26, 2026